Chronocort: Hydrocortisone formulation for CAH in adults

Company: Diurnal Limited

  • Product Overview: First-in-class hydrocortisone product for the lifelong treatment of adrenal disorders
  • Primary Indication: Congenital Adrenal Hyperplasia, (CAH), (Orphan)
  • Secondary Indication: Adrenal Insufficiency
  • Core Differentiator: Modified release hydrocortisone that mimics the physiological rhythm of cortisol
  • Development Stage: Phase 3
  • Opportunity: Available for License